Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation.
Crit Care Explor
; 2(11): e0284, 2020 Nov.
Article
in English
| MEDLINE | ID: covidwho-939585
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 cell entry depends on angiotensin-converting enzyme 2 and transmembrane serine protease 2 and is blocked in cell culture by camostat mesylate, a clinically proven protease inhibitor. Whether camostat mesylate is able to lower disease burden in coronavirus disease 2019 sepsis is currently unknown. DESIGN:
Retrospective observational case series.SETTING:
Patient treated in ICU of University hospital Göttingen, Germany. PATIENTS Eleven critical ill coronavirus disease 2019 patients with organ failure were treated in ICU.INTERVENTIONS:
Compassionate use of camostat mesylate (six patients, camostat group) or hydroxychloroquine (five patients, hydroxychloroquine group). MEASUREMENTS AND MAINRESULTS:
Clinical courses were assessed by Sepsis-related Organ Failure Assessment score at days 1, 3, and 8. Further, viral load, oxygenation, and inflammatory markers were determined. Sepsis-related Organ Failure Assessment score was comparable between camostat and hydroxychloroquine groups upon ICU admission. During observation, the Sepsis-related Organ Failure Assessment score decreased in the camostat group but remained elevated in the hydroxychloroquine group. The decline in disease severity in camostat mesylate treated patients was paralleled by a decline in inflammatory markers and improvement of oxygenation.CONCLUSIONS:
The severity of coronavirus disease 2019 decreased upon camostat mesylate treatment within a period of 8 days and a similar effect was not observed in patients receiving hydroxychloroquine. Camostat mesylate thus warrants further evaluation within randomized clinical trials.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Language:
English
Journal:
Crit Care Explor
Year:
2020
Document Type:
Article
Affiliation country:
CCE.0000000000000284
Similar
MEDLINE
...
LILACS
LIS